These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 20611009

  • 1. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z.
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):386-7. PubMed ID: 20611009
    [No Abstract] [Full Text] [Related]

  • 2. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z.
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract] [Full Text] [Related]

  • 3. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL.
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N, Herranz L, Alvarez C, Martínez Olmos MA, Márco A, Gómez-Pan A.
    Exp Clin Endocrinol Diabetes; 1998 Apr; 106(3):226-30. PubMed ID: 9710364
    [Abstract] [Full Text] [Related]

  • 5. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S, Zilli A, Fanetti I, Ciafardini C, Conte D, Peracchi M.
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [Abstract] [Full Text] [Related]

  • 6. [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis].
    Somogyi A, Ruzicska E, Varga T, Rácz K, Nagy G.
    Orv Hetil; 2007 Sep 02; 148(35):1667-71. PubMed ID: 17720674
    [Abstract] [Full Text] [Related]

  • 7. [Diagnosis of ileal carcinoid with contrast enhanced ultrasonic diagnosis].
    Rickes S, Uhle C, Neye H, Ensberg D, Rauh P.
    Med Klin (Munich); 2009 Jul 15; 104(7):564-6. PubMed ID: 19618143
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
    Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L.
    N Engl J Med; 2000 Aug 24; 343(8):551-4. PubMed ID: 10954763
    [No Abstract] [Full Text] [Related]

  • 9. Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings.
    Ho AC, Horton KM, Fishman EK.
    Clin Imaging; 2000 Aug 24; 24(4):200-3. PubMed ID: 11274882
    [Abstract] [Full Text] [Related]

  • 10. Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis.
    Kalkan Ç, Karakaya F, Soykan İ.
    Turk J Gastroenterol; 2016 Nov 24; 27(6):515-520. PubMed ID: 27852542
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
    Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G.
    Eur J Endocrinol; 2013 Feb 24; 168(2):185-93. PubMed ID: 23132699
    [Abstract] [Full Text] [Related]

  • 12. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P.
    Endocr Relat Cancer; 2008 Mar 24; 15(1):337-42. PubMed ID: 18310299
    [Abstract] [Full Text] [Related]

  • 13. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS, Khuroo MS, Khuroo NS.
    J Gastroenterol Hepatol; 2010 Mar 24; 25(3):548-54. PubMed ID: 20074162
    [Abstract] [Full Text] [Related]

  • 14. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
    Lipp RW, Hammer HF, Passath A, Dobnig H, Ramschak-Schwarzer S, Stiegler C, Leb G, Krejs GJ.
    Acta Med Austriaca; 1993 Mar 24; 20(1-2):42-4. PubMed ID: 8475679
    [Abstract] [Full Text] [Related]

  • 15. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
    Imtiaz KE, Monteith P, Khaleeli A.
    Clin Endocrinol (Oxf); 2000 Dec 24; 53(6):755-8. PubMed ID: 11155099
    [Abstract] [Full Text] [Related]

  • 16. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
    Goñi F, Oleaga A, Goñi MJ, Monreal M, Yoldi A, González A, Llorente I, Moncada E.
    Rev Clin Esp; 1991 Nov 24; 189(7):331-4. PubMed ID: 1722585
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ECL cell carcinoids with octreotide LAR.
    Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL.
    Scand J Gastroenterol; 2004 Jul 24; 39(7):621-8. PubMed ID: 15370681
    [Abstract] [Full Text] [Related]

  • 18. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
    Lokich J.
    Am J Clin Oncol; 1998 Jun 24; 21(3):246-7. PubMed ID: 9626790
    [Abstract] [Full Text] [Related]

  • 19. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
    Leong WL, Pasieka JL.
    J Surg Oncol; 2002 Mar 24; 79(3):180-7. PubMed ID: 11870669
    [Abstract] [Full Text] [Related]

  • 20. [Analogs of somatostatin and carcinoid tumors].
    Gutiérrez Rodero F, Morales Cano JM, de Blas Laborda C, González Barber A.
    Med Clin (Barc); 1990 Jun 09; 95(2):78-9. PubMed ID: 2250512
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.